Comparison of renal outcomes between sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist in Japanese patients with type 2 diabetes and obesity.

Yukihiro Wada, Masao Toyoda, Kazuo Kobayashi, Togo Aoyama, Akira Kanamori, Yasuo Takeuchi

Abstract readComparative Study

In one paragraph

Article in Clinical and experimental nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yukihiro WadaDepartment of Nephrology, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-Ku, Sagamihara, Kanagawa, 224-0474, Japan. wada-y@kitasato-u.ac.jp.ORCID http://orcid.org/0000-0001-5996-8735

Masao ToyodaDivision of Diabetes, Metabolism, and Endocrinology, Department of Medicine, Tokai University, Isehara, Japan.

Kazuo KobayashiCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Togo AoyamaDepartment of Health Management Center, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.

Akira KanamoriCommittee of Hypertension and Kidney Disease, Kanagawa Physicians Association, Yokohama, Japan.

Yasuo TakeuchiDepartment of Nephrology, Kitasato University School of Medicine, Kitasato 1-15-1, Minami-Ku, Sagamihara, Kanagawa, 224-0474, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1Ra) have shown renoprotective effects in type 2 diabetes (T2D). Our previous findings suggested superior renal outcomes with SGLT2i compared to GLP-1Ra, particularly due to greater reductions in blood pressure (BP). However, whether this benefit extends to obese patients remains unclear. This study compared renal outcomes between SGLT2i and GLP-1Ra in obese Japanese patients with T2D.

methodsThis retrospective study included patients with T2D and body mass index ≥ 25 kg/m

resultsAfter matching (n = 89 per group), the incidence of renal events did not differ significantly between the two groups. The annual decline in eGFR tended to be smaller with SGLT2i than with GLP-1Ra (- 1.6 ± 3.5 vs. - 2.8 ± 5.8 mL/min/1.73 m

conclusionAmong this population, the annual eGFR decline appeared numerically smaller with SGLT2i-tretament, without statistical significance. Greater BP and BW reductions were observed, though their impact on renal outcomes remains uncertain.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesGlomerular Filtration RateGlucagon-Like Peptide-1 Receptor AgonistsKidneyObesitySodium-Glucose Transporter 2 InhibitorsAgedAlbuminuriaBlood PressureDisease ProgressionEast Asian PeopleFemaleHumansJapanMaleGlucagon-Like Peptide-1 Receptor AgonistsSodium-Glucose Transporter 2 InhibitorsGLP-1RaObesityRenal outcomeSGLT2i

Identifiers

PMID41838277

DOI10.1016/j.pcd.2021.08.012

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.